PURPOSE: The RAND Interstitial Cystitis Epidemiology survey estimated that 2.7% to 6.5% of United States women have urinary symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome. We describe the demographic and clinical characteristics of the symptomatic community based RAND Interstitial Cystitis Epidemiology cohort, and compare them with those of a clinically based interstitial cystitis/bladder pain syndrome cohort. MATERIALS AND METHODS: Subjects included 3,397 community women who met the criteria for the RAND Interstitial Cystitis Epidemiology high sensitivity case definition, and 277 women with an interstitial cystitis/bladder pain syndrome diagnosis recruited from specialist practices across the United States (clinical cohort). Questions focused on demographic information, symptom severity, quality of life indicators, concomitant diagnoses and treatment. RESULTS: Average symptom duration for both groups was approximately 14 years. Women in the clinical cohort reported worse baseline pain and maximum pain, although the absolute differences were small. Mean Interstitial Cystitis Symptom Index scores were approximately 11 for both groups, but mean Interstitial Cystitis Problem Index scores were 9.9 and 13.2 for the clinical cohort and the RAND Interstitial Cystitis Epidemiology cohort, respectively (p <0.001). The RAND Interstitial Cystitis Epidemiology subjects were more likely to be uninsured. CONCLUSIONS: The RAND Interstitial Cystitis Epidemiology community cohort was remarkably similar to an interstitial cystitis/bladder pain syndrome clinical cohort with respect to demographics, symptoms and quality of life measures. In contrast to other chronic pain conditions for which clinical cohorts typically report worse symptoms and functional status than population based samples, our data suggest that many measures of symptom severity and functional impact are similar, and sometimes worse, in the RAND Interstitial Cystitis Epidemiology cohort. These findings suggest that interstitial cystitis/bladder pain syndrome is significantly burdensome, and likely to be underdiagnosed and undertreated in the United States.
PURPOSE: The RAND Interstitial Cystitis Epidemiology survey estimated that 2.7% to 6.5% of United States women have urinary symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome. We describe the demographic and clinical characteristics of the symptomatic community based RAND Interstitial Cystitis Epidemiology cohort, and compare them with those of a clinically based interstitial cystitis/bladder pain syndrome cohort. MATERIALS AND METHODS: Subjects included 3,397 community women who met the criteria for the RAND Interstitial Cystitis Epidemiology high sensitivity case definition, and 277 women with an interstitial cystitis/bladder pain syndrome diagnosis recruited from specialist practices across the United States (clinical cohort). Questions focused on demographic information, symptom severity, quality of life indicators, concomitant diagnoses and treatment. RESULTS: Average symptom duration for both groups was approximately 14 years. Women in the clinical cohort reported worse baseline pain and maximum pain, although the absolute differences were small. Mean Interstitial Cystitis Symptom Index scores were approximately 11 for both groups, but mean Interstitial Cystitis Problem Index scores were 9.9 and 13.2 for the clinical cohort and the RAND Interstitial Cystitis Epidemiology cohort, respectively (p <0.001). The RAND Interstitial Cystitis Epidemiology subjects were more likely to be uninsured. CONCLUSIONS: The RAND Interstitial Cystitis Epidemiology community cohort was remarkably similar to an interstitial cystitis/bladder pain syndrome clinical cohort with respect to demographics, symptoms and quality of life measures. In contrast to other chronic pain conditions for which clinical cohorts typically report worse symptoms and functional status than population based samples, our data suggest that many measures of symptom severity and functional impact are similar, and sometimes worse, in the RAND Interstitial Cystitis Epidemiology cohort. These findings suggest that interstitial cystitis/bladder pain syndrome is significantly burdensome, and likely to be underdiagnosed and undertreated in the United States.
Authors: Sandra H Berry; Marc N Elliott; Marika Suttorp; Laura M Bogart; Michael A Stoto; Paul Eggers; Leroy Nyberg; J Quentin Clemens Journal: J Urol Date: 2011-06-16 Impact factor: 7.450
Authors: J Quentin Clemens; Richard T Meenan; Maureen C O'Keeffe Rosetti; Sheila O Brown; Sara Y Gao; Elizabeth A Calhoun Journal: J Urol Date: 2005-08 Impact factor: 7.450
Authors: B C Kersh; L A Bradley; G S Alarcón; K R Alberts; A Sotolongo; M Y Martin; L A Aaron; D F Dewaal; M L Domino; W F Chaplin; N R Palardy; L R Cianfrini; M Triana-Alexander Journal: Arthritis Rheum Date: 2001-08
Authors: J Quentin Clemens; Carol L Link; Paul W Eggers; John W Kusek; Leroy M Nyberg; John B McKinlay Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: C Arpino; M P Carrieri; G Valesini; E Pizzigallo; P Rovere; U Tirelli; F Conti; P Dialmi; A Barberio; N Rusconi; O Bosco; A Lazzarin; A Saracco; M L Moro; D Vlahov Journal: Ann Ist Super Sanita Date: 1999 Impact factor: 1.663
Authors: Sandra H Berry; Laura M Bogart; Chau Pham; Karin Liu; Leroy Nyberg; Michael Stoto; Marika Suttorp; J Quentin Clemens Journal: J Urol Date: 2010-03-29 Impact factor: 7.450
Authors: A D Sperber; S Carmel; Y Atzmon; I Weisberg; Y Shalit; L Neumann; A Fich; M Friger; D Buskila Journal: Am J Gastroenterol Date: 2000-04 Impact factor: 10.864
Authors: Lindsey C McKernan; Colin G Walsh; William S Reynolds; Leslie J Crofford; Roger R Dmochowski; David A Williams Journal: Neurourol Urodyn Date: 2017-10-09 Impact factor: 2.696
Authors: Lindsey C McKernan; Benjamin N Johnson; William S Reynolds; David A Williams; Jennifer S Cheavens; Roger R Dmochowski; Leslie J Crofford Journal: Neurourol Urodyn Date: 2018-10-23 Impact factor: 2.696